FCMV
NRIX icon

Foresite Capital Management V’s Nurix Therapeutics NRIX Stock Holding History

Foresite Capital Management V’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.11M Buy
+265,000
New +$4.39M 1.52% 8
2021
Q4 		– Sell
-451,522
Closed -$13.5M – 18
2021
Q3 		$13.5M Hold
451,522
– – 4.2% 8
2021
Q2 		$12M Hold
451,522
– – 4.71% 8
2021
Q1 		$14M Hold
451,522
– – 4.13% 7
2020
Q4 		$14.8M Buy
+451,522
New +$15M 10.99% 4

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Foresite Capital Management V's NRIX Position: Q1 2026 in Review

Foresite Capital Management V opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 265,000 shares worth $4.11M. The stake represents 1.52% of the portfolio and ranks #8 among its holdings. This is a return to the name: Foresite Capital Management V previously reported a position in NRIX as recently as Q3 2021.

Foresite Capital Management V first reported a position in NRIX in Q4 2020 and has held it in 5 quarters since. The position peaked at $14.8M in Q4 2020. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Foresite Capital Management V held 265,000 shares of Nurix Therapeutics worth $4.11M as of Q1 2026.
  • Nurix Therapeutics was a new Foresite Capital Management V position in Q1 2026.
  • Nurix Therapeutics made up 1.52% of Foresite Capital Management V's portfolio in Q1 2026, its #8 holding.
  • Foresite Capital Management V first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Foresite Capital Management V's Nurix Therapeutics position peaked at $14.8M in Q4 2020.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Foresite Capital Management V's 13F filing for Q1 2026, filed 15 May 2026.